What is Zacks Research’s Estimate for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for shares of Omnicell in a report issued on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.17 for the quarter, up from their prior forecast of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

Other analysts have also issued research reports about the company. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research note on Wednesday, October 9th. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Craig Hallum upped their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.00.

Omnicell Trading Down 0.4 %

Shares of NASDAQ:OMCL opened at $44.69 on Thursday. The business’s fifty day moving average price is $44.62 and its two-hundred day moving average price is $42.62. Omnicell has a one year low of $25.12 and a one year high of $55.74.

Institutional Trading of Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. lifted its stake in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. purchased a new stake in shares of Omnicell during the 3rd quarter valued at about $32,721,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after acquiring an additional 259,463 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in Omnicell by 27.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after acquiring an additional 243,353 shares during the period. Finally, Pier Capital LLC purchased a new position in Omnicell in the 3rd quarter worth approximately $5,859,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.64% of the stock is currently owned by insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.